Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice

Masa Ki Inoue, Yasuka Matsunaga, Yusuke Nakatsu, Takeshi Yamamotoya, Koji Ueda, Akifumi Kushiyama, Hideyuki Sakoda, Midori Fujishiro, Hiraku Ono, Misaki Iwashita, Tomomi Sano, Fusanori Nishimura, Kenichi Morii, Kensuke Sasaki, Takao Masaki, Tomoichiro Asano

Research output: Contribution to journalArticle

Abstract

Background: Recently, clinical studies have shown the protective effects of sodium glucose co-transporter2 (SGLT2) inhibitors against progression of diabetic nephropathy, but the underlying molecular mechanisms remain unclear. Methods: Diabetic mice were prepared by injecting nicotinamide and streptozotocin, followed by high-sucrose diet feeding (NA/STZ/Suc mice). The SGLT2 inhibitor canagliflozin was administered as a 0.03% (w/w) mixture in the diet for 4 weeks. Then, various parameters and effects of canagliflozin on diabetic nephropathy were investigated. Results: Canagliflozin administration to NA/STZ/Suc mice normalized hyperglycemia as well as elevated renal mRNA of collagen 1a1, 1a2, CTGF, TNFα and MCP-1. Microscopic observation revealed reduced fibrotic deposition in the kidneys of canagliflozin-treated NA/STZ/Suc mice. Interestingly, the protein level of Pin1, reportedly involved in the inflammation and fibrosis affecting several tissues, was markedly increased in the NA/STZ/Suc mouse kidney, but this was normalized with canagliflozin treatment. The cells showing increased Pin1 expression in the kidney were mainly mesangial cells, along with podocytes, based on immunohistochemical analysis. Furthermore, it was revealed that canagliflozin induced AMP-activated kinase (AMPK) activation concentration-dependently in CRL1927 mesangial as well as THP-1 macrophage cell lines. AMPK activation was speculated to suppress mesangial cell proliferation and exert anti-inflammatory effects in hematopoietic cells. Conclusion: Therefore, we can reasonably suggest that normalized Pin1 expression and AMPK activation contribute to the molecular mechanisms underlying SGLT2 inhibitor-induced suppression of diabetic nephropathy, possibly at least in part by reducing inflammation and fibrotic change.

Original languageEnglish
Article number57
JournalDiabetology and Metabolic Syndrome
Volume11
Issue number1
DOIs
Publication statusPublished - Jul 22 2019

Fingerprint

AMP-Activated Protein Kinases
Sodium
Kidney
Glucose
Diabetic Nephropathies
Mesangial Cells
Diet
Inflammation
Podocytes
Niacinamide
Streptozocin
Hyperglycemia
Sucrose
Canagliflozin
Fibrosis
Anti-Inflammatory Agents
Collagen
Macrophages
Cell Proliferation
Cell Line

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. / Inoue, Masa Ki; Matsunaga, Yasuka; Nakatsu, Yusuke; Yamamotoya, Takeshi; Ueda, Koji; Kushiyama, Akifumi; Sakoda, Hideyuki; Fujishiro, Midori; Ono, Hiraku; Iwashita, Misaki; Sano, Tomomi; Nishimura, Fusanori; Morii, Kenichi; Sasaki, Kensuke; Masaki, Takao; Asano, Tomoichiro.

In: Diabetology and Metabolic Syndrome, Vol. 11, No. 1, 57, 22.07.2019.

Research output: Contribution to journalArticle

Inoue, Masa Ki ; Matsunaga, Yasuka ; Nakatsu, Yusuke ; Yamamotoya, Takeshi ; Ueda, Koji ; Kushiyama, Akifumi ; Sakoda, Hideyuki ; Fujishiro, Midori ; Ono, Hiraku ; Iwashita, Misaki ; Sano, Tomomi ; Nishimura, Fusanori ; Morii, Kenichi ; Sasaki, Kensuke ; Masaki, Takao ; Asano, Tomoichiro. / Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. In: Diabetology and Metabolic Syndrome. 2019 ; Vol. 11, No. 1.
@article{5d63f503cd304cc0806ce8bd0a834baa,
title = "Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice",
abstract = "Background: Recently, clinical studies have shown the protective effects of sodium glucose co-transporter2 (SGLT2) inhibitors against progression of diabetic nephropathy, but the underlying molecular mechanisms remain unclear. Methods: Diabetic mice were prepared by injecting nicotinamide and streptozotocin, followed by high-sucrose diet feeding (NA/STZ/Suc mice). The SGLT2 inhibitor canagliflozin was administered as a 0.03{\%} (w/w) mixture in the diet for 4 weeks. Then, various parameters and effects of canagliflozin on diabetic nephropathy were investigated. Results: Canagliflozin administration to NA/STZ/Suc mice normalized hyperglycemia as well as elevated renal mRNA of collagen 1a1, 1a2, CTGF, TNFα and MCP-1. Microscopic observation revealed reduced fibrotic deposition in the kidneys of canagliflozin-treated NA/STZ/Suc mice. Interestingly, the protein level of Pin1, reportedly involved in the inflammation and fibrosis affecting several tissues, was markedly increased in the NA/STZ/Suc mouse kidney, but this was normalized with canagliflozin treatment. The cells showing increased Pin1 expression in the kidney were mainly mesangial cells, along with podocytes, based on immunohistochemical analysis. Furthermore, it was revealed that canagliflozin induced AMP-activated kinase (AMPK) activation concentration-dependently in CRL1927 mesangial as well as THP-1 macrophage cell lines. AMPK activation was speculated to suppress mesangial cell proliferation and exert anti-inflammatory effects in hematopoietic cells. Conclusion: Therefore, we can reasonably suggest that normalized Pin1 expression and AMPK activation contribute to the molecular mechanisms underlying SGLT2 inhibitor-induced suppression of diabetic nephropathy, possibly at least in part by reducing inflammation and fibrotic change.",
author = "Inoue, {Masa Ki} and Yasuka Matsunaga and Yusuke Nakatsu and Takeshi Yamamotoya and Koji Ueda and Akifumi Kushiyama and Hideyuki Sakoda and Midori Fujishiro and Hiraku Ono and Misaki Iwashita and Tomomi Sano and Fusanori Nishimura and Kenichi Morii and Kensuke Sasaki and Takao Masaki and Tomoichiro Asano",
year = "2019",
month = "7",
day = "22",
doi = "10.1186/s13098-019-0454-6",
language = "English",
volume = "11",
journal = "Diabetology and Metabolic Syndrome",
issn = "1758-5996",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice

AU - Inoue, Masa Ki

AU - Matsunaga, Yasuka

AU - Nakatsu, Yusuke

AU - Yamamotoya, Takeshi

AU - Ueda, Koji

AU - Kushiyama, Akifumi

AU - Sakoda, Hideyuki

AU - Fujishiro, Midori

AU - Ono, Hiraku

AU - Iwashita, Misaki

AU - Sano, Tomomi

AU - Nishimura, Fusanori

AU - Morii, Kenichi

AU - Sasaki, Kensuke

AU - Masaki, Takao

AU - Asano, Tomoichiro

PY - 2019/7/22

Y1 - 2019/7/22

N2 - Background: Recently, clinical studies have shown the protective effects of sodium glucose co-transporter2 (SGLT2) inhibitors against progression of diabetic nephropathy, but the underlying molecular mechanisms remain unclear. Methods: Diabetic mice were prepared by injecting nicotinamide and streptozotocin, followed by high-sucrose diet feeding (NA/STZ/Suc mice). The SGLT2 inhibitor canagliflozin was administered as a 0.03% (w/w) mixture in the diet for 4 weeks. Then, various parameters and effects of canagliflozin on diabetic nephropathy were investigated. Results: Canagliflozin administration to NA/STZ/Suc mice normalized hyperglycemia as well as elevated renal mRNA of collagen 1a1, 1a2, CTGF, TNFα and MCP-1. Microscopic observation revealed reduced fibrotic deposition in the kidneys of canagliflozin-treated NA/STZ/Suc mice. Interestingly, the protein level of Pin1, reportedly involved in the inflammation and fibrosis affecting several tissues, was markedly increased in the NA/STZ/Suc mouse kidney, but this was normalized with canagliflozin treatment. The cells showing increased Pin1 expression in the kidney were mainly mesangial cells, along with podocytes, based on immunohistochemical analysis. Furthermore, it was revealed that canagliflozin induced AMP-activated kinase (AMPK) activation concentration-dependently in CRL1927 mesangial as well as THP-1 macrophage cell lines. AMPK activation was speculated to suppress mesangial cell proliferation and exert anti-inflammatory effects in hematopoietic cells. Conclusion: Therefore, we can reasonably suggest that normalized Pin1 expression and AMPK activation contribute to the molecular mechanisms underlying SGLT2 inhibitor-induced suppression of diabetic nephropathy, possibly at least in part by reducing inflammation and fibrotic change.

AB - Background: Recently, clinical studies have shown the protective effects of sodium glucose co-transporter2 (SGLT2) inhibitors against progression of diabetic nephropathy, but the underlying molecular mechanisms remain unclear. Methods: Diabetic mice were prepared by injecting nicotinamide and streptozotocin, followed by high-sucrose diet feeding (NA/STZ/Suc mice). The SGLT2 inhibitor canagliflozin was administered as a 0.03% (w/w) mixture in the diet for 4 weeks. Then, various parameters and effects of canagliflozin on diabetic nephropathy were investigated. Results: Canagliflozin administration to NA/STZ/Suc mice normalized hyperglycemia as well as elevated renal mRNA of collagen 1a1, 1a2, CTGF, TNFα and MCP-1. Microscopic observation revealed reduced fibrotic deposition in the kidneys of canagliflozin-treated NA/STZ/Suc mice. Interestingly, the protein level of Pin1, reportedly involved in the inflammation and fibrosis affecting several tissues, was markedly increased in the NA/STZ/Suc mouse kidney, but this was normalized with canagliflozin treatment. The cells showing increased Pin1 expression in the kidney were mainly mesangial cells, along with podocytes, based on immunohistochemical analysis. Furthermore, it was revealed that canagliflozin induced AMP-activated kinase (AMPK) activation concentration-dependently in CRL1927 mesangial as well as THP-1 macrophage cell lines. AMPK activation was speculated to suppress mesangial cell proliferation and exert anti-inflammatory effects in hematopoietic cells. Conclusion: Therefore, we can reasonably suggest that normalized Pin1 expression and AMPK activation contribute to the molecular mechanisms underlying SGLT2 inhibitor-induced suppression of diabetic nephropathy, possibly at least in part by reducing inflammation and fibrotic change.

UR - http://www.scopus.com/inward/record.url?scp=85069780185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069780185&partnerID=8YFLogxK

U2 - 10.1186/s13098-019-0454-6

DO - 10.1186/s13098-019-0454-6

M3 - Article

AN - SCOPUS:85069780185

VL - 11

JO - Diabetology and Metabolic Syndrome

JF - Diabetology and Metabolic Syndrome

SN - 1758-5996

IS - 1

M1 - 57

ER -